The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Tóm tắt
Từ khóa
Tài liệu tham khảo
2012, The diagnosis and management of non‐alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, Hepatology, 55, 2005, 10.1002/hep.25762
2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD
2016, Management of NAFLD: a stage‐based approach, Nat Rev Gastroenterol Hepatol, 13, 196, 10.1038/nrgastro.2016.3
2016, Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Hepatology, 64, 2234, 10.1002/hep.28699
2015, Pharmacotherapy for nonalcoholic fatty liver disease, Semin Liver Dis, 35, 338, 10.1055/s-0035-1562951
2016, Non‐alcoholic fatty liver disease and liver transplantation, Metabolism, 65, 1208, 10.1016/j.metabol.2016.02.013
2016, Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease, Gastroenterology, 150, 1811, 10.1053/j.gastro.2016.03.008
2015, Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes, Clin Gastroenterol Hepatol, 13, 2062, 10.1016/j.cgh.2015.07.029
2014, Development of new fatty liver, or resolution of existing fatty liver, over five years of follow‐up, and risk of incident hypertension, J Hepatol, 60, 1040, 10.1016/j.jhep.2014.01.009
2015, Incidence of non‐alcoholic fatty liver disease in Hong Kong: a population study with paired proton‐magnetic resonance spectroscopy, J Hepatol, 62, 182, 10.1016/j.jhep.2014.08.041
2016, Metabolically healthy obesity and the development of nonalcoholic fatty liver disease, Am J Gastroenterol, 111, 1133, 10.1038/ajg.2016.178
2007, Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs, Clin Med, 7, 119, 10.7861/clinmedicine.7-2-119
2012, Predictors for incidence and remission of NAFLD in the general population during a seven‐year prospective follow‐up, J Hepatol, 56, 1145, 10.1016/j.jhep.2011.12.011
2016, Global epidemiology of nonalcoholic fatty liver disease‐Meta‐analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431
2016, Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis, Expert Rev Gastroenterol Hepatol, 10, 63, 10.1586/17474124.2016.1099433
2015, NAFLD: a multisystem disease, J Hepatol, 62, S47
2009, Epidemiology and natural history of non‐alcoholic steatohepatitis, Clin Liver Dis, 13, 511, 10.1016/j.cld.2009.07.005
2011, Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008, Clin Gastroenterol Hepatol, 9, 524, 10.1016/j.cgh.2011.03.020
2015, Current and emerging medications for overweight or obesity in people with comorbidities, Diabetes Obes Metab, 17, 1021, 10.1111/dom.12502
2016, Extrahepatic manifestations of nonalcoholic fatty liver disease, Curr Hepatol Rep, 15, 75, 10.1007/s11901-016-0295-9
2014, Bariatric surgery and non‐alcoholic fatty liver disease: current and potential future treatments, Front Endocrinol., 5, 164
2015, Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery, Surg Obes Relat Dis, 11, 137, 10.1016/j.soard.2014.06.015
2009, Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus, Liver Int, 29, 113, 10.1111/j.1478-3231.2008.01718.x
2009, Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus, J Assoc Physicians India, 57, 205
2016, Sex‐specific association between serum uric acid and nonalcoholic fatty liver disease in type 2 diabetic patients, J Diabetes Res, 2016, 3805372
2013, Nonalcoholic fatty liver: a possible new target for type 2 diabetes prevention and treatment, Int J Mol Sci, 14, 22933, 10.3390/ijms141122933
2000, Fatty infiltration of liver in hyperlipidemic patients, Dig Dis Sci, 45, 1929, 10.1023/A:1005661516165
2016, Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high‐density lipoprotein cholesterol, J Clin Lipidol, 10, 420, 10.1016/j.jacl.2015.12.026
2009, Chronic liver disease among Alaska‐Native people, 2003‐2004, Am J Gastroenterol, 104, 363, 10.1038/ajg.2008.57
2008, Chronic liver disease among two American Indian patient populations in the southwestern United States, 2000‐2003, J Clin Gastroenterol, 42, 949
2016, The prevalence of metabolic syndrome in non‐alcoholic fatty liver disease; a population‐based study, Middle East J Dig Dis, 8, 131, 10.15171/mejdd.2016.18
2004, Factors associated or related to with pathological severity of nonalcoholic fatty liver disease, Korean J Intern Med, 19, 19, 10.3904/kjim.2004.19.1.19
2012, Prevalence and risk factors of non‐alcoholic fatty liver disease in the elderly: results from the Rotterdam study, J Hepatol, 57, 1305, 10.1016/j.jhep.2012.07.028
2004, Non‐alcoholic fatty liver disease—a common and benign finding in octogenarian patients, Liver Int, 24, 588, 10.1111/j.1478-3231.2004.0969.x
2006, Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures, Liver Int, 26, 856, 10.1111/j.1478-3231.2006.01311.x
2013, Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals, Ann N Y Acad Sci, 1281, 106, 10.1111/nyas.12016
2013, Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment, Curr Pharm Des, 19, 5219, 10.2174/13816128113199990381
1999, Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis, Hepatology, 30, 1356, 10.1002/hep.510300604
2013, Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients, Hepatology, 58, 1644, 10.1002/hep.26465
2015, Liver fibrosis, but no other histologic features, is associated with long‐term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043
2011, Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States, Gastroenterology, 141, 1249, 10.1053/j.gastro.2011.06.061
2007, Incidence and natural course of fatty liver in the general population: the Dionysos study, Hepatology, 46, 1387, 10.1002/hep.21827
2011, Meta‐analysis: natural history of non‐alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non‐invasive tests for liver disease severity, Ann Med, 43, 617, 10.3109/07853890.2010.518623
2011, Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x
2014, Liver transplantation and non‐alcoholic fatty liver disease, World J Gastroenterol, 20, 15532, 10.3748/wjg.v20.i42.15532
2010, Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up, Hepatology, 51, 595, 10.1002/hep.23314
2004, Long term prognosis of fatty liver: risk of chronic liver disease and death, Gut, 53, 750, 10.1136/gut.2003.019984
2009, Long‐term follow‐up of patients with nonalcoholic fatty liver, Clin Gastroenterol Hepatol, 7, 234, 10.1016/j.cgh.2008.11.005
2017, Variables associated with inpatient and outpatient resource utilization among Medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis, J Clin Gastroenterol, 51, 254, 10.1097/MCG.0000000000000567
2005, The natural history of nonalcoholic fatty liver disease: a population‐based cohort study, Gastroenterology, 129, 113, 10.1053/j.gastro.2005.04.014
2016, Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver‐related morbidity and mortality, Gastroenterology, 150, 1778, 10.1053/j.gastro.2016.03.005
2016, Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world, Clin Liver Dis, 20, 205, 10.1016/j.cld.2015.10.001
2016, Global, regional, and national life expectancy, all‐cause mortality, and cause‐specific mortality for 249 causes of death, 1980‐2015: a systematic analysis for the Global Burden of Disease Study 2015, Lancet, 388, 1459, 10.1016/S0140-6736(16)31012-1
2011, Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver‐related mortality, Hepatology, 53, 1874, 10.1002/hep.24268
2011, Non‐alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS), Scand J Gastroenterol, 46, 479, 10.3109/00365521.2010.539251
2016, Characterization of hepatocellular carcinoma (HCC) in non‐alcoholic fatty liver disease (NAFLD) patients without cirrhosis, Hepatol Int, 10, 632, 10.1007/s12072-015-9679-0
2015, Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009, Hepatology, 62, 1723, 10.1002/hep.28123
2016, Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 14, 124, 10.1016/j.cgh.2015.07.019
2009, NASH and cryptogenic cirrhosis: a histological analysis, Ann Hepatol, 8, 346, 10.1016/S1665-2681(19)31748-X
2016, Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Metabolism, 65, 1080, 10.1016/j.metabol.2015.11.008
2015, Nonalcoholic fatty liver disease and hepatic cirrhosis: comparison with viral hepatitis‐associated steatosis, World J Gastroenterol, 21, 12989, 10.3748/wjg.v21.i46.12989
2016, Lower rates of receiving model for end‐stage liver disease exception and longer time to transplant among non‐alcoholic steatohepatitis hepatocellular carcinoma, Liver Transpl, 22, 1356, 10.1002/lt.24507
2015, Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States, Gastroenterology, 148, 547, 10.1053/j.gastro.2014.11.039
2011, Endpoints and clinical trial design for nonalcoholic steatohepatitis, Hepatology, 54, 344, 10.1002/hep.24376
2012, What should we recommend to our patients with NAFLD regarding alcohol use?, Am J Gastroenterol, 107, 976, 10.1038/ajg.2012.20
2015, Gaps in recognition and evaluation of incidentally identified hepatic steatosis, Dig Dis Sci, 60, 333, 10.1007/s10620-014-3346-5
2015, High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels, J Clin Endocrinol Metab, 100, 2231, 10.1210/jc.2015-1966
2016, Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study, Hepatology, 63, 138, 10.1002/hep.27981
2016, Screening diabetic patients for non‐alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study, Gut, 65, 1359, 10.1136/gutjnl-2015-309265
2016, Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost‐effectiveness analysis, Dig Dis Sci, 61, 2108, 10.1007/s10620-016-4044-2
2016, Not routine screening, but vigilance for chronic liver disease in patients with type 2 diabetes, J Hepatol, 64, 1211, 10.1016/j.jhep.2016.02.032
2009, Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort, Obesity (Silver Spring), 17, 1240, 10.1038/oby.2009.4
2006, Familial aggregation of insulin resistance in first‐degree relatives of patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 4, 1162, 10.1016/j.cgh.2006.06.001
2000, Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds, Am J Med, 108, 9, 10.1016/S0002-9343(99)00315-0
2001, Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease, Am J Gastroenterol, 96, 2957, 10.1111/j.1572-0241.2001.04667.x
2009, Heritability of nonalcoholic fatty liver disease, Gastroenterology, 136, 1585, 10.1053/j.gastro.2009.01.050
2012, Heritability of non‐alcoholic fatty liver disease and association with abnormal vascular parameters: a twin study, Liver Int, 32, 1287, 10.1111/j.1478-3231.2012.02823.x
2009, Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins, J Hepatol, 50, 1035, 10.1016/j.jhep.2008.12.025
2015, Heritability of hepatic fibrosis and steatosis based on a prospective twin study, Gastroenterology, 149, 1784, 10.1053/j.gastro.2015.08.011
2012, Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease, Hepatology, 55, 77, 10.1002/hep.24706
2010, HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease, Gastroenterology, 138, 905, 10.1053/j.gastro.2009.11.013
2012, Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network, Hepatol Int, 6, 379, 10.1007/s12072-011-9277-8
2008, Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non‐alcoholic fatty liver disease, J Hepatol, 48, 829, 10.1016/j.jhep.2008.01.016
2016, Risk of type 2 diabetes in patients with non‐alcoholic fatty liver disease: causal association or epiphenomenon?, Diabetes Metab, 42, 142, 10.1016/j.diabet.2016.04.002
2013, Liver fat content, evaluated through semi‐quantitative ultrasound measurement, is associated with impaired glucose profiles: a community‐based study in Chinese, PLoS One, 8, e65210, 10.1371/journal.pone.0065210
2015, Liver fat, statin use, and incident diabetes: the multi‐ethnic study of atherosclerosis, Atherosclerosis, 242, 211, 10.1016/j.atherosclerosis.2015.07.018
2011, Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy, J Magn Reson Imaging, 34, spcone
2016, A comparison of liver fat content as determined by magnetic resonance imaging‐proton density fat fraction and MRS versus liver histology in non‐alcoholic fatty liver disease, Acta Radiol, 57, 271, 10.1177/0284185115580488
2016, Accuracy and the effect of possible subject‐based confounders of magnitude‐based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference, J Magn Reson Imaging, 43, 398, 10.1002/jmri.25006
2013, Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials, Hepatology, 58, 1930, 10.1002/hep.26455
2016, Controlled attenuation parameter for the diagnosis of steatosis in non‐alcoholic fatty liver disease, J Gastroenterol Hepatol, 31, 848, 10.1111/jgh.13219
2009, Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management, Hepatology, 49, 306, 10.1002/hep.22603
2003, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome, Hepatology, 37, 917, 10.1053/jhep.2003.50161
2006, Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD, Am J Gastroenterol, 101, 2247, 10.1111/j.1572-0241.2006.00719.x
2005, Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease, Diabetes Care, 28, 1222, 10.2337/diacare.28.5.1222
2013, In patients with non‐alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not, Metabolism, 62, 352, 10.1016/j.metabol.2012.08.005
2014, Limited value of plasma cytokeratin‐18 as a biomarker for NASH and fibrosis in patients with non‐alcoholic fatty liver disease, J Hepatol, 60, 167, 10.1016/j.jhep.2013.07.042
2014, Serum cytokeratin‐18 in the diagnosis of non‐alcoholic steatohepatitis: a meta‐analysis, Hepatol Res, 44, 854, 10.1111/hepr.12197
2016, Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016, Dig Dis Sci, 61, 1356, 10.1007/s10620-016-4079-4
2016, Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography, Gastroenterology, 150, 626, 10.1053/j.gastro.2015.11.048
2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496
2016, The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 111, 677, 10.1038/ajg.2016.49
2015, Deficiency of eNOS exacerbates early‐stage NAFLD pathogenesis by changing the fat distribution, BMC Gastroenterol, 15, 177, 10.1186/s12876-015-0409-9
2015, Transient elastography is feasible with high success rate for evaluation of non‐alcoholic fatty liver disease (NAFLD) in a multicenter setting, Hepatology, 62, 1290A
2013, Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography, Radiology, 268, 411, 10.1148/radiol.13121193
2014, Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study, Hepatology, 60, 1920, 10.1002/hep.27362
2012, Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non‐alcoholic fatty liver disease in Japanese, PLoS One, 7, e38322, 10.1371/journal.pone.0038322
2011, Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease, Hepatology, 53, 1883, 10.1002/hep.24283
2010, The association of genetic variability in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease, Hepatology, 52, 894, 10.1002/hep.23759
2010, PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease, Hepatology, 52, 904, 10.1002/hep.23768
2014, TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non‐alcoholic fatty liver disease, Nat Commun, 5, 4309, 10.1038/ncomms5309
2014, Exome‐wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, 46, 352, 10.1038/ng.2901
2015, Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease, Hepatology, 61, 506, 10.1002/hep.27490
2016, The rs2294918 E434K variant modulates patatin‐like phospholipase domain‐containing 3 expression and liver damage, Hepatology, 63, 787, 10.1002/hep.28370
2016, The MBOAT7‐TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent, Gastroenterology, 150, 1219, 10.1053/j.gastro.2016.01.032
2015, Intrapulpal temperature changes during root surface irradiation with dual‐wavelength laser (2780 and 940 nm): in vitro study, J Biomed Opt, 20, 018002, 10.1117/1.JBO.20.1.018002
2014, A histologic scoring system for prognosis of patients with alcoholic hepatitis, Gastroenterology, 146, 1231, 10.1053/j.gastro.2014.01.018
2008, Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis, Gastroenterology, 135, 1961, 10.1053/j.gastro.2008.08.050
2005, Histopathology of pediatric nonalcoholic fatty liver disease, Hepatology, 42, 641, 10.1002/hep.20842
2012, Association between puberty and features of nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 10, 786, 10.1016/j.cgh.2012.01.020
2012, Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research, Semin Liver Dis, 32, 3, 10.1055/s-0032-1306421
2014, Pathological features of fatty liver disease, Gastroenterology, 147, 754, 10.1053/j.gastro.2014.07.056
2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701
2012, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 56, 1751, 10.1002/hep.25889
2014, Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease, Hepatology, 60, 565, 10.1002/hep.27173
2005, Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, 128, 1898, 10.1053/j.gastro.2005.03.084
2007, Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux‐en‐Y bypass, Clin Gastroenterol Hepatol, 5, 1329, 10.1016/j.cgh.2007.06.005
2009, Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 7, 481, 10.1016/j.cgh.2008.12.015
2012, Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non‐alcoholic fatty liver disease (NAFLD): a systematic review and meta‐analysis of randomised trials, Diabetologia, 55, 885, 10.1007/s00125-011-2446-4
2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005
2004, Long‐term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans, Proc Natl Acad Sci U S A, 101, 6659, 10.1073/pnas.0308291101
2009, Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction, Gastroenterology, 136, 1552, 10.1053/j.gastro.2009.01.048
2011, Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects, Hepatology, 53, 1504, 10.1002/hep.24242
2011, Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease, Am J Gastroenterol, 106, 460, 10.1038/ajg.2010.488
2006, Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease, Gastroenterology, 130, 2023, 10.1053/j.gastro.2006.03.019
2009, Independent effects of physical activity in patients with nonalcoholic fatty liver disease, Hepatology, 50, 68, 10.1002/hep.22940
2016, Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver, J Hepatol, 65, 791, 10.1016/j.jhep.2016.05.026
2009, Long‐term effectiveness of diet‐plus‐exercise interventions vs. diet‐only interventions for weight loss: a meta‐analysis, Obes Rev, 10, 313, 10.1111/j.1467-789X.2008.00547.x
2011, Bilateral traumatic chylothorax treated by thoracic duct embolization: a rare treatment for an uncommon problem, Vasc Med, 16, 284, 10.1177/1358863X11408747
2004, Metformin in the treatment of patients with non‐alcoholic steatohepatitis, Aliment Pharmacol Ther, 19, 537, 10.1111/j.1365-2036.2004.01888.x
2004, Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial, Aliment Pharmacol Ther, 20, 23, 10.1111/j.1365-2036.2004.02025.x
2005, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease, Am J Gastroenterol., 100, 1082, 10.1111/j.1572-0241.2005.41583.x
2009, Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis, Aliment Pharmacol Ther, 29, 172, 10.1111/j.1365-2036.2008.03869.x
2009, The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial, Ther Adv Gastroenterol, 2, 157, 10.1177/1756283X09105462
2009, Metformin in patients with non‐alcoholic fatty liver disease: a randomized, controlled trial, Scand J Gastroenterol, 44, 853, 10.1080/00365520902845268
2008, Clinical trial: insulin‐sensitizing agents may reduce consequences of insulin resistance in individuals with non‐alcoholic steatohepatitis, Aliment Pharmacol Ther, 28, 200, 10.1111/j.1365-2036.2008.03723.x
2007, Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions, Ann. Hepatol, 6, 222, 10.1016/S1665-2681(19)31902-7
2009, The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease, Acta Diabetol, 46, 113, 10.1007/s00592-008-0067-2
2010, Efficacy of insulin‐sensitizing agents in nonalcoholic fatty liver disease, Eur J Gastroenterol Hepatol, 22, 18, 10.1097/MEG.0b013e32832e2baf
2013, Metformin in non‐alcoholic fatty liver disease: a systematic review and meta‐analysis, Biomed Rep, 1, 57, 10.3892/br.2012.18
2010, A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease, Hepatology, 52, 79, 10.1002/hep.23623
2014, Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes, Cell Metab, 20, 573, 10.1016/j.cmet.2014.08.005
2012, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications, Gastroenterology, 142, 711, 10.1053/j.gastro.2012.02.003
2008, Rosiglitazone for nonalcoholic steatohepatitis: one‐year results of the randomized placebo‐controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial, Gastroenterology, 135, 100, 10.1053/j.gastro.2008.03.078
2010, Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial, Hepatology, 51, 445, 10.1002/hep.23270
2013, The cardiovascular safety of diabetes drugs—insights from the rosiglitazone experience, N Engl J Med, 369, 1285, 10.1056/NEJMp1309610
2006, A placebo‐controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326
2016, Long‐term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial, Ann Intern Med, 165, 305, 10.7326/M15-1774
2008, Randomized, placebo‐controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis, Gastroenterology, 135, 1176, 10.1053/j.gastro.2008.06.047
2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056/NEJMoa0907929
2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle‐aged population utilizing ultrasound and liver biopsy: a prospective study, Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038
2013, The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus, Curr Diab Rep, 13, 329, 10.1007/s11892-013-0378-8
2015, Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis, Diabetologia, 58, 493, 10.1007/s00125-014-3456-9
2016, Pioglitazone use and risk of bladder cancer: population based cohort study, BMJ, 352, i1541
2015, Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes, JAMA, 314, 265, 10.1001/jama.2015.7996
2015, Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN‐J), Hepatol Res, 45, 269, 10.1111/hepr.12351
2016, Liraglutide safety and efficacy in patients with non‐alcoholic steatohepatitis (LEAN): a multicentre, double‐blind, randomised, placebo‐controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X
2013, Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program, Aliment Pharmacol Ther, 37, 234, 10.1111/apt.12149
2010, Exenatide in the treatment of diabetic patients with non‐alcoholic steatohepatitis: a case series, Am J Gastroenterol, 105, 2707, 10.1038/ajg.2010.363
2007, Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open‐label, uncontrolled extension of three double‐blind, placebo‐controlled trials, Clin Ther, 29, 139, 10.1016/j.clinthera.2007.01.015
2001, Plasma transforming growth factor‐beta1 level and efficacy of alpha‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study, Aliment Pharmacol Ther, 15, 1667, 10.1046/j.1365-2036.2001.01083.x
2003, Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis, Am J Gastroenterol, 98, 2485, 10.1111/j.1572-0241.2003.08699.x
2006, Randomized placebo‐controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 4, 1537, 10.1016/j.cgh.2006.09.025
2004, A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 2, 1107, 10.1016/S1542-3565(04)00457-4
2007, Effects of vitamin E treatment on peroxisome proliferator‐activated receptor‐alpha expression and insulin resistance in patients with non‐alcoholic steatohepatitis: results of a pilot study, Intern Med J, 37, 229, 10.1111/j.1445-5994.2006.01295.x
2011, Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial, JAMA, 305, 1659, 10.1001/jama.2011.520
2015, Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta‐analysis of randomized controlled trials, Nutrition, 31, 923, 10.1016/j.nut.2014.11.018
2015, Association between vitamin E and non‐alcoholic steatohepatitis: a meta‐analysis, Int J Clin Exp Med, 8, 3924
2005, Meta‐analysis: high‐dosage vitamin E supplementation may increase all‐cause mortality, Ann Intern Med, 142, 37, 10.7326/0003-4819-142-1-200501040-00110
2009, The questionable association of vitamin E supplementation and mortality—inconsistent results of different meta‐analytic approaches, Cell Mol Biol, 55, OL1111
2011, Vitamin E and all‐cause mortality: a meta‐analysis, Curr Aging Sci, 4, 158, 10.2174/1874609811104020158
2011, Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA, 306, 1549, 10.1001/jama.2011.1437
2014, Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk, J Natl Cancer Inst, 106, djt456
2016, Selenium‐ or vitamin E‐related gene variants, interaction with supplementation, and risk of high‐grade prostate cancer in SELECT, Cancer Epidemiol Biomark Prev, 25, 1050, 10.1158/1055-9965.EPI-16-0104
2011, Long‐term prevention of mortality in morbid obesity through bariatric surgery. A systematic review and meta‐analysis of trials performed with gastric banding and gastric bypass, Ann Surg, 253, 484, 10.1097/SLA.0b013e31820d98cb
2007, Long‐term mortality after gastric bypass surgery, N Engl J Med, 357, 753, 10.1056/NEJMoa066603
2007, Effects of bariatric surgery on mortality in Swedish obese subjects, N Engl J Med, 357, 741, 10.1056/NEJMoa066254
2009, Prospective study of the long‐term effects of bariatric surgery on liver injury in patients without advanced disease, Gastroenterology, 137, 532, 10.1053/j.gastro.2009.04.052
2015, Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients, Gastroenterology, 149, 379, 10.1053/j.gastro.2015.04.014
2015, Bariatric surgery and non‐alcoholic fatty liver disease: a systematic review of liver biochemistry and histology, Obes Surg, 25, 2280, 10.1007/s11695-015-1691-x
2011, Increased perioperative mortality following bariatric surgery among patients with cirrhosis, Clin Gastroenterol Hepatol, 9, 897, 10.1016/j.cgh.2011.07.007
2015, A systematic review of bariatric surgery in patients with liver cirrhosis, Obes Surg, 25, 1518, 10.1007/s11695-015-1727-2
1996, Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: a pilot study, Hepatology, 23, 1464, 10.1002/hep.510230624
2010, High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial, Hepatology, 52, 472, 10.1002/hep.23727
2004, Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial, Hepatology, 39, 770, 10.1002/hep.20092
2011, A randomized controlled trial of high‐dose ursodesoxycholic acid for nonalcoholic steatohepatitis, J Hepatol, 54, 1011, 10.1016/j.jhep.2010.08.030
2006, Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study, Aliment Pharmacol Ther, 23, 1143, 10.1111/j.1365-2036.2006.02885.x
2010, Review article: omega‐3 fatty acids—a promising novel therapy for non‐alcoholic fatty liver disease, Aliment Pharmacol Ther, 31, 679, 10.1111/j.1365-2036.2009.04230.x
2014, Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study, Hepatology, 60, 1211, 10.1002/hep.27289
2014, No significant effects of ethyl‐eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial, Gastroenterology, 147, 377, 10.1053/j.gastro.2014.04.046
2008, Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease, Hepatology, 47, 1947, 10.1002/hep.22292
2009, Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population, Am J Gastroenterol, 104, 2189, 10.1038/ajg.2009.361
2007, Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia, Am J Gastroenterol, 102, 1912, 10.1111/j.1572-0241.2007.01274.x
2011, Alcohol consumption appears to protect against non‐alcoholic fatty liver disease, Aliment Pharmacol Ther, 33, 378, 10.1111/j.1365-2036.2010.04520.x
2001, Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese, Gastroenterology, 121, 91, 10.1053/gast.2001.25540
2009, Effects of light‐to‐moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients, Eur J Gastroenterol Hepatol, 21, 969, 10.1097/MEG.0b013e328328f3ec
2012, Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non‐alcoholic fatty liver disease (NAFLD), J Hepatol, 57, 384, 10.1016/j.jhep.2012.03.024
2016, How safe is moderate alcohol consumption in overweight and obese individuals?, Gastroenterology, 150, 1698, 10.1053/j.gastro.2016.01.002
2006, Long‐term follow‐up of patients with NAFLD and elevated liver enzymes, Hepatology, 44, 865, 10.1002/hep.21327
2016, Fatty liver is an independent predictor of early carotid atherosclerosis, J Hepatol, 65, 95, 10.1016/j.jhep.2016.02.023
2016, Non‐alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications, J Hepatol, 65, 425, 10.1016/j.jhep.2016.04.005
2014, Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile, Lipids Health Dis, 13, 100, 10.1186/1476-511X-13-100
2015, Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile, Clin Gastroenterol Hepatol, 13, 1000, 10.1016/j.cgh.2014.10.008
2016, Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD, J Clin Endocrinol Metab, 101, 644, 10.1210/jc.2015-3111
2010, Safety and efficacy of long‐term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post‐hoc analysis, Lancet, 376, 1916, 10.1016/S0140-6736(10)61272-X
2013, Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild‐to‐moderate baseline elevations in alanine aminotransferase levels, Int J Cardiol, 168, 3846, 10.1016/j.ijcard.2013.06.024
2015, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129, S1
2004, Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity, Gastroenterology, 126, 1287, 10.1053/j.gastro.2004.02.015
2007, Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial, Hepatology, 46, 1453, 10.1002/hep.21848
2011, Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial, Am J Gastroenterol, 106, 71, 10.1038/ajg.2010.299
2010, Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH, J Gastroenterol, 45, 750, 10.1007/s00535-010-0203-y
2007, Statins in non‐alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow‐up study, J Hepatol, 47, 135, 10.1016/j.jhep.2007.02.013
2008, Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia, Metabolism, 57, 1711, 10.1016/j.metabol.2008.07.030
2009, A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo‐controlled trial, J Clin Gastroenterol, 43, 990, 10.1097/MCG.0b013e31819c392e
2015, Farnesoid X nuclear receptor ligand obeticholic acid for non‐cirrhotic, non‐alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo‐controlled trial, Lancet, 385, 956, 10.1016/S0140-6736(14)61933-4
2016, Elafibranor, an agonist of the peroxisome proliferator‐activated receptor‐α and ‐δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening, Gastroenterology, 150, 1147, 10.1053/j.gastro.2016.01.038
2011, Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis, Hepatology, 54, 555, 10.1002/hep.24418
2011, Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants, Clin Gastroenterol Hepatol, 9, 700, 10.1016/j.cgh.2011.04.007
2002, Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States, Hepatology, 35, 105, 10.1053/jhep.2002.30318
2013, Increased morbidity in overweight and obese liver transplant recipients: a single‐center experience of 1325 patients from the United Kingdom, Liver Transpl, 19, 551, 10.1002/lt.23618
2008, The impact of obesity on long‐term outcomes in liver transplant recipients—results of the NIDDK liver transplant database, Am J Transplant, 8, 667, 10.1111/j.1600-6143.2007.02100.x
2013, Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end‐stage liver disease, Am J Transplant, 13, 363, 10.1111/j.1600-6143.2012.04318.x
2013, Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study, Clin Endocrinol (Oxf), 78, 525, 10.1111/j.1365-2265.2012.04433.x
2012, Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value, Liver Transpl, 18, 1209, 10.1002/lt.23495
2014, Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study, Hepatology, 59, 1772, 10.1002/hep.26716
2014, Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation, Liver Transpl, 20, 640, 10.1002/lt.23863
2014, Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography, J Hepatol, 60, 1151, 10.1016/j.jhep.2014.02.026
2005, Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients, Nutrition, 21, 113, 10.1016/j.nut.2004.02.002
2000, Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end‐stage liver disease, Liver Transpl, 6, 575, 10.1053/jlts.2000.9736
2010, Prevalence of non‐alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes, J Hepatol, 53, 713, 10.1016/j.jhep.2010.04.030
2013, A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?, Atherosclerosis, 230, 258, 10.1016/j.atherosclerosis.2013.07.052
2012, Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation, J Am Coll Cardiol, 60, 434, 10.1016/j.jacc.2012.05.008
2016, Nonalcoholic steatohepatitis is the most rapidly growing indication for simultaneous liver kidney transplantation in the United States, Transplantation, 100, 607, 10.1097/TP.0000000000000945
2012, Estimating glomerular filtration rate from serum creatinine and cystatin C, N Engl J Med, 367, 20, 10.1056/NEJMoa1114248
2000, Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases, Transplantation, 70, 292, 10.1097/00007890-200007270-00009
2010, Non‐alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil, Am J Gastroenterol, 105, 613, 10.1038/ajg.2009.717
2017, Long term outcomes in patients undergoing liver transplantation for nonalcoholic steatohepatitis related cirrhosis, Transplantation, 101, 1867, 10.1097/TP.0000000000001709
1998, Weight change and obesity after liver transplantation: incidence and risk factors, Liver Transpl Surg, 4, 285, 10.1002/lt.500040402
2011, Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events, Liver Transpl, 17, 15, 10.1002/lt.22198
2002, Mechanisms involved in the side effects of glucocorticoids, Pharmacol Ther, 96, 23, 10.1016/S0163-7258(02)00297-8
2011, Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS‐1E beta‐cells, Br J Pharmacol, 162, 136, 10.1111/j.1476-5381.2010.01018.x
2017, Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases, Hepatology, 65, 310, 10.1002/hep.28906
2017, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology
2006, Prevalence of fatty liver in children and adolescents, Pediatrics, 118, 1388, 10.1542/peds.2006-1212
2015, The prevalence of non‐alcoholic fatty liver disease in children and adolescents: a systematic review and meta‐analysis, PLoS One, 10, e0140908, 10.1371/journal.pone.0140908
2014, Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease, J Pediatr, 164, 699, 10.1016/j.jpeds.2013.10.072
2014, Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels, J Pediatr, 164, 707, 10.1016/j.jpeds.2013.10.071
2013, Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non‐alcoholic fatty liver disease, Aliment Pharmacol Ther, 38, 1267, 10.1111/apt.12518
2009, The natural history of non‐alcoholic fatty liver disease in children: a follow‐up study for up to 20 years, Gut, 58, 1538, 10.1136/gut.2008.171280
2012, The natural history of nonalcoholic fatty liver disease in children and adolescents assessed in placebo recipients in the TONIC trial, Hepatology, 56, 905A
2005, Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists, J Pediatr, 147, 839, 10.1016/j.jpeds.2005.07.020
2007, Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report, Pediatrics, 120, S164
2009, Advances in pediatric nonalcoholic fatty liver disease, Hepatology, 50, 1282, 10.1002/hep.23119
2015, A comprehensive review of noninvasive liver fibrosis tests in pediatric nonalcoholic fatty liver disease, Curr Gastroenterol Rep, 17, 23, 10.1007/s11894-015-0447-z
2011, A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis, Clin Gastroenterol Hepatol, 9, 150, 10.1016/j.cgh.2010.09.015
2009, Performance of ELF serum markers in predicting fibrosis stage in pediatric non‐alcoholic fatty liver disease, Gastroenterology, 136, 160, 10.1053/j.gastro.2008.09.013
2014, Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 12, 2121, 10.1016/j.cgh.2014.05.010
2009, Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study, Hepatology, 50, 1113, 10.1002/hep.23133
2017, In children with nonalcoholic fatty liver disease, zone 1 steatosis is associated with advanced fibrosis, Clin Gastroenterol Hepatol
2006, Effect of vitamin E on aminotransferase levels and insulin resistance in children with non‐alcoholic fatty liver disease, Aliment Pharmacol Ther, 24, 1553, 10.1111/j.1365-2036.2006.03161.x
2008, Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial, Hepatology, 48, 119, 10.1002/hep.22336
2016, Intensive lifestyle treatment for non‐alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment, Int J Obes (Lond), 40, 51, 10.1038/ijo.2015.175
2002, Management of child and adolescent obesity: summary and recommendations based on reports from pediatricians, pediatric nurse practitioners, and registered dietitians, Pediatrics, 110, 236, 10.1542/peds.110.S1.236
2016, In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores, Gastroenterology, 151, 1141, 10.1053/j.gastro.2016.08.027
2015, Omega‐3 Fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial, J Pediatr, 166, 1358, 10.1016/j.jpeds.2015.01.056
2015, A double‐blind, placebo‐controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease, Nutr Metab Cardiovasc Dis, 25, 734, 10.1016/j.numecd.2015.04.003